vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Verisign (VRSN). Click either name above to swap in a different company.
Verisign is the larger business by last-quarter revenue ($425.3M vs $284.0M, roughly 1.5× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 48.5%, a 47.8% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 7.6%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 5.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.
ACAD vs VRSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $425.3M |
| Net Profit | $273.6M | $206.2M |
| Gross Margin | 90.8% | 88.5% |
| Operating Margin | 6.1% | 67.0% |
| Net Margin | 96.3% | 48.5% |
| Revenue YoY | 9.4% | 7.6% |
| Net Profit YoY | 90.3% | 7.7% |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $425.3M | ||
| Q3 25 | $278.6M | $419.1M | ||
| Q2 25 | $264.6M | $409.9M | ||
| Q1 25 | $244.3M | $402.3M | ||
| Q4 24 | $259.6M | $395.4M | ||
| Q3 24 | $250.4M | $390.6M | ||
| Q2 24 | $242.0M | $387.1M | ||
| Q1 24 | $205.8M | $384.3M |
| Q4 25 | $273.6M | $206.2M | ||
| Q3 25 | $71.8M | $212.8M | ||
| Q2 25 | $26.7M | $207.4M | ||
| Q1 25 | $19.0M | $199.3M | ||
| Q4 24 | $143.7M | $191.5M | ||
| Q3 24 | $32.8M | $201.3M | ||
| Q2 24 | $33.4M | $198.8M | ||
| Q1 24 | $16.6M | $194.1M |
| Q4 25 | 90.8% | 88.5% | ||
| Q3 25 | 92.2% | 88.4% | ||
| Q2 25 | 92.2% | 88.0% | ||
| Q1 25 | 91.7% | 87.7% | ||
| Q4 24 | 91.6% | 87.8% | ||
| Q3 24 | 92.5% | 88.0% | ||
| Q2 24 | 92.5% | 87.8% | ||
| Q1 24 | 88.8% | 87.2% |
| Q4 25 | 6.1% | 67.0% | ||
| Q3 25 | 12.8% | 67.8% | ||
| Q2 25 | 12.2% | 68.5% | ||
| Q1 25 | 7.9% | 67.4% | ||
| Q4 24 | 59.1% | 66.7% | ||
| Q3 24 | 12.6% | 68.9% | ||
| Q2 24 | 12.6% | 68.8% | ||
| Q1 24 | 7.4% | 67.4% |
| Q4 25 | 96.3% | 48.5% | ||
| Q3 25 | 25.8% | 50.8% | ||
| Q2 25 | 10.1% | 50.6% | ||
| Q1 25 | 7.8% | 49.5% | ||
| Q4 24 | 55.4% | 48.4% | ||
| Q3 24 | 13.1% | 51.5% | ||
| Q2 24 | 13.8% | 51.4% | ||
| Q1 24 | 8.0% | 50.5% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $580.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $-2.2B |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $580.5M | ||
| Q3 25 | $258.0M | $617.7M | ||
| Q2 25 | $253.6M | $593.8M | ||
| Q1 25 | $217.7M | $648.5M | ||
| Q4 24 | $319.6M | $599.9M | ||
| Q3 24 | $155.1M | $644.9M | ||
| Q2 24 | $177.1M | $689.9M | ||
| Q1 24 | $204.7M | $924.7M |
| Q4 25 | $1.2B | $-2.2B | ||
| Q3 25 | $917.3M | $-2.1B | ||
| Q2 25 | $822.4M | $-2.0B | ||
| Q1 25 | $765.2M | $-2.0B | ||
| Q4 24 | $732.8M | $-2.0B | ||
| Q3 24 | $577.2M | $-1.9B | ||
| Q2 24 | $516.7M | $-1.8B | ||
| Q1 24 | $464.0M | $-1.6B |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $976.9M | $1.5B | ||
| Q2 24 | $914.1M | $1.5B | ||
| Q1 24 | $855.1M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $289.6M |
| Free Cash FlowOCF − Capex | — | $285.1M |
| FCF MarginFCF / Revenue | — | 67.0% |
| Capex IntensityCapex / Revenue | — | 1.1% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $289.6M | ||
| Q3 25 | $74.3M | $307.7M | ||
| Q2 25 | $64.0M | $202.5M | ||
| Q1 25 | $20.3M | $291.3M | ||
| Q4 24 | $40.4M | $231.5M | ||
| Q3 24 | $63.2M | $253.4M | ||
| Q2 24 | $25.0M | $160.4M | ||
| Q1 24 | $29.1M | $257.3M |
| Q4 25 | — | $285.1M | ||
| Q3 25 | $73.9M | $303.0M | ||
| Q2 25 | — | $194.7M | ||
| Q1 25 | — | $285.5M | ||
| Q4 24 | — | $222.0M | ||
| Q3 24 | $63.2M | $247.8M | ||
| Q2 24 | — | $151.2M | ||
| Q1 24 | — | $253.5M |
| Q4 25 | — | 67.0% | ||
| Q3 25 | 26.5% | 72.3% | ||
| Q2 25 | — | 47.5% | ||
| Q1 25 | — | 71.0% | ||
| Q4 24 | — | 56.1% | ||
| Q3 24 | 25.2% | 63.4% | ||
| Q2 24 | — | 39.1% | ||
| Q1 24 | — | 66.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | 0.1% | 1.1% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | -0.18× | 1.40× | ||
| Q3 25 | 1.03× | 1.45× | ||
| Q2 25 | 2.40× | 0.98× | ||
| Q1 25 | 1.07× | 1.46× | ||
| Q4 24 | 0.28× | 1.21× | ||
| Q3 24 | 1.93× | 1.26× | ||
| Q2 24 | 0.75× | 0.81× | ||
| Q1 24 | 1.76× | 1.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
VRSN
Segment breakdown not available.
